Current estimates suggest a global glaucoma prevalence of over 60 million cases. And, with an aging population, this prevalence is growing rapidly. Most cases are associated with elevated intraocular pressure. However, despite the availability of drugs that reduce intraocular pressure, visual impairment and vision loss remain a problem. While mostcases are associated with elevated intraocular pressure, approximately 25% of cases have normal intraocular pressure. Patients are frequently treated with drugs to reduce intraocular pressure, simply because physicians lack therapeutic options At Connexin Therapeutics, they are developing the options ophthalmologists need to preserve vision in their patients with glaucoma and related conditions.

Therapeutics

Connexin Therapeutics Ltd.

Connexin Therapeutics Ltd.'s headquarters in Cambridge, United Kingdom

Description

People

Jobs